Related Experiment Video
Updated: Apr 13, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Hepatitis C infection in hemodialysis patients: A review
Digdem Ozer Etik1, Serkan Ocal1, Ahmet Sedat Boyacioglu1
1Digdem Ozer Etik, Serkan Ocal, Ahmet Sedat Boyacioglu, Department of Gastroenterology, Baskent University, 06000 Ankara, Turkey.
Insights
Hepatitis C virus (HCV) infection significantly impacts patients with end-stage renal disease (ESRD). Early diagnosis and treatment of HCV before kidney transplantation (KT) improve survival rates and prevent post-transplant complications.
Area of Science:
- Nephrology
- Hepatology
- Virology
Background:
- Hepatitis C virus (HCV)-related liver disease is a major cause of death in end-stage renal disease (ESRD) patients undergoing dialysis or kidney transplantation (KT).
- HCV-infected renal transplant recipients have a better survival rate than those on dialysis waiting lists.
- Early diagnosis and treatment of HCV before KT are crucial for preventing post-transplant complications and reducing mortality.
Purpose of the Study:
- To review the significance of HCV infection in ESRD patients.
- To evaluate diagnostic and treatment strategies for HCV in ESRD patients.
- To discuss the implications of HCV treatment on KT outcomes.
Main Methods:
- Review of existing literature on HCV in ESRD patients.
- Discussion of diagnostic methods including anti-HCV antibodies, HCV RNA, and liver biopsy for fibrosis staging.
- Analysis of treatment options such as interferon monotherapy and combination therapy with ribavirin.
Main Results:
- Conventional and pegylated interferon monotherapy show similar efficacy and safety in HCV-infected hemodialysis patients, with sustained viral responses (SVRs) around 30-40%.
- Combination therapy with interferon and ribavirin is supported by limited reports for ESRD patients, requiring careful monitoring.
- Patients achieving SVR are strong candidates for KT.
Conclusions:
- Early and effective management of HCV infection in ESRD patients is vital for improving outcomes, particularly for those awaiting or undergoing KT.
- Liver biopsy is valuable for staging fibrosis and guiding treatment decisions.
- ESRD patients with advanced liver disease may benefit from combined liver-KT evaluation.
Abstract:
Hepatitis C virus (HCV)-related liver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) who is treated with dialysis or kidney transplantation (KT). The survival rate for HCV-infected renal transplant recipients is better than that for HCV-infected hemodialysis patients on transplant waiting lists. Early diagnosis and treatment HCV infection prior to KT prevents complications post-transplantation and reduces mortality. In addition to screening for anti-HCV antibodies and detecting HCV RNA, percutaneous liver biopsy is particularly valuable for assessing the stage of liver damage in HCV-infected patients, because the stage of fibrosis is important determining optimal treatment for HCV. Studies have been demonstrated that with conventional interferon (IFN) monotherapy or pegylated IFN monotherapy are similar efficacy and safety in HCV-infected hemodialysis patients. Sustained viral responses (SVRs) with these monotherapies have ranged approximately 30% to 40%. Limited reports support the use of IFN and ribavirin combination therapy as antiviral treatment for ESRD patients or patients on hemodialysis. Ribavirin can be started at low dose and careful monitoring for side effects. Patients that show SVR after treatment are strong candidates for KT. It is also generally accepted that ESRD patients with decompensated cirrhosis and portal hypertension should be referred to the liver transplant team for consideration of combined liver-KT.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hepatitis
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

